{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:05:32Z","timestamp":1770483932328,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s12325-012-0019-7","type":"journal-article","created":{"date-parts":[[2012,5,20]],"date-time":"2012-05-20T12:43:40Z","timestamp":1337517820000},"page":"401-415","source":"Crossref","is-referenced-by-count":9,"title":["Blood Pressure Control with Angiotensin Receptor Blocker-Based Three-Drug Combinations: Key Trials"],"prefix":"10.1007","volume":"29","author":[{"given":"Alejandro","family":"de la Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","volume":"371","author":"C.M. Lawes","year":"2008","unstructured":"Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513\u20131518.","journal-title":"Lancet"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560\u20132572.","journal-title":"JAMA"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G. Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105\u20131187.","journal-title":"J Hypertens"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"780F800","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","volume":"56","author":"J.M. Flack","year":"2010","unstructured":"Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780F800.","journal-title":"Hypertension"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/HYPERTENSIONAHA.108.115212","volume":"52","author":"G. Parati","year":"2008","unstructured":"Parati G, Bilo G. Clinical relevance of day-by-day blood pressure and heart rate variability: new information from home self-measurements. Hypertension. 2008;52:1006\u20131008.","journal-title":"Hypertension"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"291S","DOI":"10.1016\/S0895-7061(01)02174-4","volume":"14","author":"W.J. Elliott","year":"2001","unstructured":"Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens. 2001;14:291S\u2013295S.","journal-title":"Am J Hypertens"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/00004872-199816110-00016","volume":"16","author":"G. Parati","year":"1998","unstructured":"Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685\u20131691.","journal-title":"J Hypertens"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0140-6736(09)60526-2","volume":"373","author":"G. Parati","year":"2009","unstructured":"Parati G, Pickering TG. Home blood-pressure monitoring: US and European consensus. Lancet. 2009;373:876\u2013878.","journal-title":"Lancet"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/HJH.0b013e328308da66","volume":"26","author":"G. Parati","year":"2008","unstructured":"Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505\u20131526.","journal-title":"J Hypertens"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000170138.56903.7a","volume":"46","author":"E. Dolan","year":"2005","unstructured":"Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156\u2013161.","journal-title":"Hypertension"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group.","year":"1991","unstructured":"SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255\u20133264.","journal-title":"JAMA"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L. Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755\u20131762.","journal-title":"Lancet"},{"key":"19_CR13","first-page":"141","volume":"1","author":"G.L. Bakris","year":"1999","unstructured":"Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: Achieve blood pressure goals. J Clin Hypertens (Greenwich). 1999;1:141\u2013147.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"C.J. Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805\u20132816.","journal-title":"JAMA"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B. Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial \u2014 Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895\u2013906.","journal-title":"Lancet"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"D.S. Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G. Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121\u20132158.","journal-title":"J Hypertens"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","volume":"124","author":"B.M. Egan","year":"2011","unstructured":"Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046\u20131058.","journal-title":"Circulation"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","volume":"54","author":"D.A. Calhoun","year":"2009","unstructured":"Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32\u201339.","journal-title":"Hypertension"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","volume":"32","author":"S. Oparil","year":"2010","unstructured":"Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252\u20131269.","journal-title":"Clin Ther"},{"key":"19_CR21","unstructured":"European Medicines Agency. Assessment report for Exforge HCT (Procedure No: EMEA\/H\/C\/001068. Doc Ref: EMEA\/CHMP\/410729\/2009). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001068\/WC500033644.pdf . Accessed Mar 9 2011."},{"issue":"Suppl.1","key":"19_CR22","first-page":"A30","volume":"12","author":"S. Chrysant","year":"2010","unstructured":"Chrysant S, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension: Analysis by age and gender. J Clin Hypertens (Greenwich). 2010;12(Suppl. 1):A30\u2013A31.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl.1","key":"19_CR23","first-page":"A39","volume":"12","author":"T. Littlejohn III","year":"2010","unstructured":"Littlejohn III T, Toth P, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) \u2014 the TRINITY study: a subgroup analysis by race. J Clin Hypertens (Greenwich). 2010;12(Suppl. 1):A39.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jash.2011.09.003","volume":"6","author":"S.G. Chrysant","year":"2012","unstructured":"Chrysant SG, Izzo JL, Jr., Kereiakes DJ, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6:132\u2013141.","journal-title":"J Am Soc Hypertens"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1751-7176.2011.00544.x","volume":"13","author":"I. JL Jr.","year":"2011","unstructured":"Izzo JL, Jr., Chrysant SG, Kereiakes DJ, et al. 24-Hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. J Clin Hypertens (Greenwich). 2011;13:873\u2013880.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/jhh.2010.115","volume":"25","author":"Y. Lacourciere","year":"2011","unstructured":"Lacourciere Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25:615\u2013622.","journal-title":"J Hum Hypertens"},{"issue":"Suppl.1","key":"19_CR27","first-page":"A70","volume":"13","author":"S. Chrysant","year":"2011","unstructured":"Chrysant S, Kereiakes DJ, Oparil S, et al. Long-term efficacy and safety of combination olmesartan medoxomil (OM)\/amlodipine besylate (AML) hydrochlorothiazide (HCTZ) in study participants with hypertension based on age: the TRINITY study. J Clin Hypertens (Greenwich). 2011;13(Suppl. 1):A70\u2013A71.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl.1","key":"19_CR28","first-page":"A75","volume":"13","author":"S. Oparil","year":"2011","unstructured":"Oparil S, Izzo J, Chrysant S, et al. Long-term efficacy and safety of combination olmesartan medoxomil (OM)\/amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) \u2014 the TRINITY study: subgroup analyses based on study participant diabetes status and BMI. J Clin Hypertens (Greenwich). 2011;13(Suppl. 1):A75\u2013A76.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.282.6.539","volume":"282","author":"J.A. Staessen","year":"1999","unstructured":"Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539\u2013546.","journal-title":"JAMA"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/HYPERTENSIONAHA.107.090084","volume":"50","author":"A. Tatasciore","year":"2007","unstructured":"Tatasciore A, Renda G, Zimarino M, et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension. 2007;50:325\u2013332.","journal-title":"Hypertension"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ageing\/afm193","volume":"37","author":"M.L. Burr","year":"2008","unstructured":"Burr ML, Dolan E, O\u2019Brien EW, O\u2019Brien ET, McCormack P. The value of ambulatory blood pressure in older adults: the Dublin outcome study. Age Ageing. 2008;37:201\u2013206.","journal-title":"Age Ageing"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/HJH.0b013e3282f97854","volume":"26","author":"D. Conen","year":"2008","unstructured":"Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26:1290\u20131299.","journal-title":"J Hypertens"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1056\/NEJMra060433","volume":"354","author":"T.G. Pickering","year":"2006","unstructured":"Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368\u20132374.","journal-title":"N Engl J Med"},{"key":"19_CR34","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use: Summary of positive opinion for Exforge HCT (Doc Ref: EMEA\/CHMP\/450701\/20092009). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/001068\/WC500059840.pdf . Accessed Mar 9 2011."},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"W.J. Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201\u2013207.","journal-title":"Lancet"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0895-7061(01)02178-1","volume":"14","author":"F.H. Messerli","year":"2001","unstructured":"Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001;14:978\u2013979.","journal-title":"Am J Hypertens"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M. Burnier","year":"2001","unstructured":"Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904\u2013912.","journal-title":"Circulation"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","volume":"30","author":"S.G. Chrysant","year":"2008","unstructured":"Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587\u2013604.","journal-title":"Clin Ther"},{"key":"19_CR39","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/jhh.2010.5","volume":"24","author":"S.G. Chrysant","year":"2010","unstructured":"Chrysant SG, Lee J, Melino M, Karki S, Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24:730\u2013738.","journal-title":"J Hum Hypertens"},{"issue":"Suppl.1","key":"19_CR40","first-page":"A111","volume":"12","author":"D. Kereiakes","year":"2010","unstructured":"Kereiakes D, Sachson RA, Qian C, Patel M. Efficacy and onset of antihypertensive effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and type 2 diabetes. J Clin Hypertens (Greenwich). 2010;12(Suppl. 1):A111\u2013A112.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"19_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1753944710374745","volume":"4","author":"H. Punzi","year":"2010","unstructured":"Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4:209\u2013221.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"T. Philipp","year":"2007","unstructured":"Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563\u2013580.","journal-title":"Clin Ther"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1524-6175.2007.06689.x","volume":"9","author":"T.R. Smith","year":"2007","unstructured":"Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9:355\u2013364.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00003495-200868030-00008","volume":"68","author":"G.L. Plosker","year":"2008","unstructured":"Plosker GL, Robinson DM. Amlodipine\/Valsartan: fixed-dose combination in hypertension. Drugs. 2008;68:373\u2013381.","journal-title":"Drugs"},{"key":"19_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3810\/pgm.2011.11.2492","volume":"123","author":"S.G. Chrysant","year":"2011","unstructured":"Chrysant SG. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgraduate Med. 2011;123:21\u201331.","journal-title":"Postgraduate Med"},{"key":"19_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IBPC.S6562","volume":"4","author":"C.L. Laffer","year":"2011","unstructured":"Laffer CL, Elijovich F. A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals. Integr Blood Press Control. 2011;4:1\u20135.","journal-title":"Integr Blood Press Control"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-012-0019-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0019-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:56:02Z","timestamp":1559462162000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0019-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0019-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}